ADARx shows heavy insider buying of $54.4M (2.865% of market cap) and an industry growth-leader ranking, but it is a binary-outcome biotech with below-average quality and no usable price this run.
Thesis pillars
- Below Average Business Quality↓Deteriorating
- Heavy Insider Buying→Stable
- Industry Growth Leader→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Oct 11, 2026
ADARx Pharmaceuticals, Inc. (ADRX) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $17.95: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that... Read more
Sell if holding. Engine safety override at $17.95: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 6.2/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — ADARx Pharmaceuticals, Inc.
Latest news
- NEWS TD Cowen Initiates Coverage On Adarx Pharmaceuticals with Buy Rating — benzinga Oct 20, 2026 positive
- NEWS JP Morgan Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $38 — benzinga Oct 20, 2026 positive
- NEWS This Restaurant Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday — benzinga Oct 20, 2026 positive
- NEWS UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35 — benzinga Oct 20, 2026 positive
- NEWS Morgan Stanley Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $32 — benzinga Oct 20, 2026 positive
Generated 2026-10-29T11:08:50Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.95: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $16.69. Score 6.2/10, moderate confidence.
Analyst target: $29.11 (+62.2% upside). Prior stop was $16.69. Stop-loss: $16.69.
Quality below floor (3.4 < 4.0).
ADARx Pharmaceuticals, Inc. trades at a P/E of N/A (forward -11.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
What does ADARx Pharmaceuticals, Inc. do?ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA...
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.